What is the Onesource Specialty Pharma PE ratio today?
Onesource Specialty Pharma's PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit over the last four quarters (Q3 FY26 to Q2 FY27) was a loss of ₹1.6 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹17,999 crore at ₹1,569.60 a share.
What is the Onesource Specialty Pharma PB ratio (price to book value)?
Onesource Specialty Pharma's price-to-book (PB) ratio is 3.04 at the 29 October 2026 close: a market capitalisation of ₹17,999 crore divided by shareholders' equity (book value) of ₹5,921 crore on 30 September 2026. That is a book value of ₹516.34 per share against a share price of ₹1,569.60.
What is the Onesource Specialty Pharma net worth?
Onesource Specialty Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹5,921 crore on 30 September 2026, up 0.3% from ₹5,904 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹17,999 crore at the 29 October 2026 close.
What is the Onesource Specialty Pharma market cap?
Onesource Specialty Pharma's market capitalisation was ₹17,999 crore at the 29 October 2026 close: 11.47 crore shares at ₹1,569.60 each.
Is Onesource Specialty Pharma debt free?
No. Onesource Specialty Pharma had borrowings of ₹1,484 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.25. Its cash and current investments were ₹38.6 crore, so its net debt was ₹1,445 crore.
What is the Onesource Specialty Pharma EPS?
Onesource Specialty Pharma's basic earnings per share (EPS) were −₹6.44 in FY26, against −₹1.63 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to −₹0.15.
What is the Onesource Specialty Pharma debt to equity ratio?
Onesource Specialty Pharma's debt-to-equity ratio was 0.25 on 30 September 2026: borrowings of ₹1,484 crore against total equity of ₹5,921 crore. A year earlier, on 30 September 2025, it was 0.18.
What is the Onesource Specialty Pharma book value per share?
Onesource Specialty Pharma's book value per share was ₹516.34 on 30 September 2026: shareholders' equity of ₹5,921 crore divided by the 11.47 crore shares in issue, up 0.1% from ₹515.58 a year earlier. The share price at the 29 October 2026 close was ₹1,569.60.
What is the Onesource Specialty Pharma revenue and profit in FY26?
In FY26 (April 2025–March 2026), Onesource Specialty Pharma's consolidated net loss was ₹73.8 crore, wider than the loss of ₹18 crore in FY25, on revenue from operations of ₹1,422 crore (down 1.6%).
What is the Onesource Specialty Pharma ROE and ROCE?
In FY26, Onesource Specialty Pharma's return on equity (ROE) was −1.3% and its return on capital employed (ROCE) was 0.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).
What is the Onesource Specialty Pharma promoter holding?
Promoters held 30.47% of Onesource Specialty Pharma on 30 September 2026, down 0.01 percentage points from 30.48% the previous quarter and up 0.70 percentage points from 29.77% a year earlier, according to the shareholding pattern filed with NSE.
What is the Onesource Specialty Pharma free cash flow?
In FY26, Onesource Specialty Pharma generated ₹8.5 crore of cash from operations and spent ₹569 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹561 crore. In FY25 it was −₹21.5 crore.
What is the Onesource Specialty Pharma shareholding pattern?
On 30 September 2026, Onesource Specialty Pharma's shares were held by promoters 30.47%, foreign portfolio investors (FII/FPI) 19.46%, domestic institutions (DII) 24.21% (including mutual funds at 13.76%) and retail and other non-institutional investors 25.86%. Over the year, FII holding was up 0.07 percentage points from 19.39% and DII holding was up 5.72 percentage points from 18.49%.
How does Onesource Specialty Pharma compare with its peers?
On FY26 consolidated figures, against Strides Pharma Science, Divi's Labs and Gland Pharma: Onesource Specialty Pharma's operating margin of 1.8% is the lowest of the four (Strides Pharma Science 14.9%, Divi's Labs 28.2%, Gland Pharma 18.8%; peer average 20.6%); its return on equity of −1.3% is the lowest of the four (Strides Pharma Science 19.7%, Divi's Labs 16.2%, Gland Pharma 10.5%; peer average 15.5%).
Onesource Specialty Pharma vs Strides Pharma Science: how do they compare?
In FY26, Onesource Specialty Pharma earned net profit of ₹73.8 crore on revenue of ₹1,422 crore, against ₹556 crore on ₹4,859 crore for Strides Pharma Science. Onesource Specialty Pharma's operating margin was 1.8% (Strides Pharma Science 14.9%) and its return on equity −1.3% (Strides Pharma Science 19.7%). At the 29 October 2026 close, Onesource Specialty Pharma's market capitalisation was ₹17,999 crore against ₹10,116 crore for Strides Pharma Science.
What are the Onesource Specialty Pharma latest quarterly results?
Onesource Specialty Pharma's latest results are for Q2 FY27 (July–September 2026), filed on 27 October 2026: consolidated net profit ₹57.5 crore, up 448.2% from ₹10.5 crore in Q2 FY26; revenue from operations ₹516 crore, up 37.4% year on year.
When are the Onesource Specialty Pharma next results?
Onesource Specialty Pharma has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
